Endometrioid stromal sarcoma (ESS) of ovary is very rare disease. These mesenchymal neoplasms occur most commonly in the uterus and occasionally originate from extra-uterine sites, such as the ovary. It is often associated with endometriosis of the ovary. Here we present this rare case to emphasize on the clinicopathologic features and fertility-sparing surgery outcome of ovarian ESS in patients with endometriosis.
INTRODUCTION
Primary endometrioid stromal sarcomas (ESS) of the ovary are rare mesenchymal tumors. It occurs in women over wide age range of 11 years to 76 years accounting for only 0.2% of all uterine malignancies and for 10%-15% of primary uterine sarcomas [1] . ESS is originated from cells that resemble those of the endometrial stroma during the proliferative phase of the menstrual cycle [2] . When uterine in location, ESS is easy to diagnose because of their characteristic histology and patterns of invasion. However, when they occur at extrauterine sites, they produce nongynecologic signs and symptoms. The majority of extrauterine ESS arises from endometriosis, suggesting that most of these tumors originate by malignant transformation of the stromal component of endometriosis [3] . ESS arising from endometriosis is commonly well differentiated and considered as an indolent tumor with good prognosis.
We recently encountered a case of ESS with endometriosis in pre-menopause woman. To provide an insight into the sites of occurrence, clinicopathologic features and fertility-sparing surgery outcome of ESS, we report a case of ESS with endometriosis with literature review.
CASE REPORT
A 25-year-old, unmarried woman came to gynecology outpatient department with the complaint of both ovarian mass which was noticed January, 2013, by accidently. Her menstrual cycles were regular but were associated with dysmenorrhoea. Routine papanicolaou smear showed reactive cellular changes with inflammation. sue. Specimen retrieval bag was used for contained removal of adnexal masses because of the concern regarding spread of malig- Immunohistochemically, tumors express vimentin, muscle markers like desmin, muscle-specific actin and α-smooth muscle actin, and progesterone receptors [8] . Recent studies have described the unique expression of CD10 in endometrial stromal cells as well as in ESS, which was proven diagnostically useful in the distinction of ESS from smooth muscle neoplasms like lowgrade leiomyosarcoma [9] . Other study suggests CD 34 might be helpful in diagnosing extrauterine extraovarian ESS [10] .
Tumors with less than 10 mitosis per 10 high power fields (HPF) are classified as low grade and those with 10 or more as high grade.
Chang et al. [11] reported that neither mitotic index nor cytologic atypia in primary extrauterine endometrial stromal neoplasm were predictive of tumor recurrence or death from tumor. In their study, 77% of patients whose tumors had a mitotic index of less than 10 per HPF had one or more recurrences and 30% died from their neoplasm. [4] . Also there is no clear evidence about effectiveness of radiotherapy and progesterone therapy. The risk of recurrence is as high as 50% along with interval for recurrence and a median interval of about three years from hysterectomy to relapse [12] . Because performing fertility-sparing surgery for lowgrade ESS is rare, and because the long-term follow-up results are still lacking, it is not possible to draw any definitive conclusion about its safety.
Low
In conclusion, ovarian ESS has an indolent clinical course, and is associated with a favorable prognosis; ovary-sparing procedures might be considered in younger patient. However, no standard treatment strategy has yet been established. Future investigation should include more study participants and focus on the response to treatment and prognosis.
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